Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6948818 | 0.76 | CYP1A2 (0.50) | ALDH1A1CYP1A2CYP3A4LMNACYP2D6 | |
| SCHEMBL16147020 | 0.75 | PDE4A (0.47) | CYP1A2CYP3A4CYP2D6CYP2C19KMT2A | |
| SCHEMBL10507124 | 0.71 | AR (0.51) | ALDH1A1CYP1A2CYP3A4LMNACYP2D6 | |
| SCHEMBL10506880 | 0.70 | AR (0.51) | ALDH1A1CYP1A2CYP3A4LMNACYP2C19 | |
| SCHEMBL4916438 | 0.68 | EGFR (0.56) | ALDH1A1CYP1A2CYP3A4LMNACYP2D6 | |
| SCHEMBL301933 | 0.67 | ALDH1A1 (0.69) | ALDH1A1ARTSHRKMT2AMEN1 | |
| SCHEMBL16146865 | 0.67 | KDM4E (0.30) | KDM4E | |
| SCHEMBL10508062 | 0.66 | AR (0.52) | ALDH1A1CYP2C19ARTSHRENPP1 | |
| SCHEMBL8343552 | 0.66 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPK1ARTSHR | |
| Ammonia Solution, Strong SCHEMBL10338964 | 0.66 | ALDH1A1 (0.67) | ALDH1A1ARTSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060253263-A1 | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy | MESHKIN BRIAN J | 2006-11-09 | — | — | US | claimed |
| EP-4736889-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | Yale University (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | SAWYER MICHAEL BRUCE (CA) | 2026-03-17 | — | — | US | disclosed |
| EP-4021496-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | UNIV YALE (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12485180-B2 | Compositions and methods for delivery of nucleic acids to cells | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240285774-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | YALE UNIVERSITY (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240285775-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | YALE UNIVERSITY (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240190998-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | YALE UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| US-12005121-B2 | Compositions and methods for delivery of nucleic acids to cells | YALE UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| EP-3782636-B1 | RAPADOCINS, INHIBITORS OF EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20120151635-A1 | METHODS OF AFFECTING NITROGEN ASSIMILATION IN PLANTS | NEW YORK UNIVERSITY | 2012-06-14 | — | — | US | disclosed |
| US-20060253263-A1 | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy | MESHKIN BRIAN J | 2006-11-09 | — | — | US | disclosed |
| US-20050256034-A1 | Dioxolane analogs for improved inter-cellular delivery | ATTARDO GIORGIO | 2005-11-17 | — | — | US | disclosed |
| EP-1324997-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | Shire Biochem Inc. (CA) | 2003-07-09 | — | — | EP | disclosed |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SHIRE BIOCHEM INC. (CA) | 2003-01-16 | — | — | US | disclosed |
| EP-0755255-A4 | TREATMENT OF TOXOPLASMOSIS | RES CORP TECHNOLOGIES INC (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002030922-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | SHIRE BIOCHEM INC. (CA) | 2002-04-18 | — | — | WO | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256034-A1 | Dioxolane analogs for improved inter-cellular delivery | SLC19A1, SLC29A1, SLC29A2 | ALDH1A1 367/4885CYP1A2 2032/4885CYP3A4 3640/4885 |
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | ADORA2A, ADORA2B, ABCG2 | ALDH1A1 3132/4885CYP1A2 2362/4885CYP3A4 1770/4885 |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SLC19A1, SLC29A1, SLC29A2 | ALDH1A1 329/4885CYP1A2 2007/4885CYP3A4 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.